Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.

SG&A Expenses: A Decade of Strategic Financial Maneuvers

__timestampBausch Health Companies Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 201420263000007461000
Thursday, January 1, 2015268270000013047000
Friday, January 1, 2016281000000011253000
Sunday, January 1, 2017258200000013933000
Monday, January 1, 2018247300000029514000
Tuesday, January 1, 2019255400000037121000
Wednesday, January 1, 2020236700000067929000
Friday, January 1, 20212624000000118818000
Saturday, January 1, 20222625000000159371000
Sunday, January 1, 20232917000000213894000
Loading chart...

Unveiling the hidden dimensions of data

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to cost management.

From 2014 to 2023, Bausch Health's SG&A expenses have shown a steady increase, peaking at nearly 2.9 billion USD in 2023, reflecting a 44% rise from 2014. This trend underscores their expansive operational strategy. In contrast, BioCryst Pharmaceuticals, Inc. has seen a dramatic surge in SG&A expenses, skyrocketing by over 2700% from 2014 to 2023, reaching approximately 214 million USD. This sharp increase highlights their aggressive growth and investment in administrative capabilities.

These insights reveal the strategic financial maneuvers of two distinct players in the pharmaceutical sector, offering a window into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025